Journal
CANCERS
Volume 11, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/cancers11081133
Keywords
mucosal melanoma; BRAF; NRAS; mutations; MAPK; targeted therapies
Categories
Funding
- INSERM
- Fondation ARC pour la Recherche sur le Cancer [PJA2017206199]
- Ligue Nationale Contre le Cancer [RS17/75-20]
- Universite Paris Diderot
- Gefluc Paris-IDF
- Vaincre le melanome
Ask authors/readers for more resources
Primary mucosal melanomas represent a minority of melanomas, but have a significantly worse prognosis than cutaneous melanomas. A better characterization of the molecular pathogenesis of this melanoma subtype could help us understand the risk factors associated with the development of mucosal melanomas and highlight therapeutic targets. Because the Mitogen-Activated Protein Kinase (MAPK) pathway plays such a significant role in melanoma development, we explore v-raf murine sarcoma viral oncogene homolog B (BRAF) and neuroblastoma RAS viral oncogene homolog (NRAS) mutations in mucosal melanoma and compare them to the mutation profiles in cutaneous melanoma and other tumors with BRAF and NRAS mutations. We show that in addition to being less frequent, BRAF and NRAS mutations are different in mucosal melanoma compared to cutaneous melanomas. Strikingly, the BRAF and NRAS mutation profiles in mucosal melanoma are closer to those found in cancers such as lung cancer, suggesting that mutations in mucosal melanoma could be linked to some genotoxic agents that remain to be identified. We also show that the atypical BRAF and NRAS mutations found in mucosal melanomas have particular effects on protein activities, which could be essential for the transformation of mucosal melanocytes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available